Bright Minds Biosciences Inc. (DRUG)
NEO-L 
Summary
DRUG Chart
Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating
Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resistant epilepsies. DRUG's BMB-101 achieved -73.1% and -63.3% median seizure reductions in Absence Epilepsy and DEE cohorts, respectively. Multiple 2026 catalysts include additional phase 2 data, phase 3 trial initiation, and a phase 2 PWS study for BMB-101.
Bright Minds Biosciences has standout year with epilepsy drug in Phase II trials
For three decades, central nervous system (CNS) drug development was a tough space for investors, scarred by failed bets on Alzheimer's disease, plateauing first-generation antidepressants, and setbacks in safety and efficacy. But advances in receptor-selective chemistry and so-called “biased agonism” – steering toward therapeutic pathways and away from areas that cause side effects – are reviving interest in the field.
Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why
Bright Minds Biosciences Inc. (DRUG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Bright Minds Biosciences Inc. (DRUG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bright Minds Biosciences Inc. ever had a stock split?
Bright Minds Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ian McDonald CEO | NEO-L Exchange | CA10919W4056 ISIN |
| CA Country | 26 Employees | - Last Dividend | 14 Jul 2023 Last Split | 22 Mar 2021 IPO Date |
Overview
Bright Minds Biosciences Inc., established in 2017 and based in New York, New York, is a biotechnology firm focused on developing advanced therapeutic solutions aimed at significantly enhancing the quality of life for patients grappling with severe and life-altering diseases. The company operates predominantly within the United States and dedicates its research to creating selective 5-HT receptor agonists. These developments are designed to target a range of issues including epilepsy, pain, and various neuropsychiatric conditions. Bright Minds Biosciences boasts a significant collaborative network, working alongside prestigious institutions such as the National Institutes of Health, University of Texas Medical Branch, and Medical College of Wisconsin to advance its research and treatment efficacy for conditions like epilepsy, impulse control disorders, and beyond.
Products and Services
- 5-HT2C, 5-HT2A, and 5-HT2C/A receptor agonists
These selective serotonin receptor agonists are part of the company’s robust portfolio developed for the treatment of epilepsy, pain, and neuropsychiatry. By targeting specific serotonin receptors, these compounds aim to offer precise and effective management of symptoms associated with each condition.
- BMB-101
Currently completing a phase 1 trial, BMB-101 is specifically designed for an undisclosed seizure disorder. This promising therapeutic candidate showcases the company's commitment to addressing the complexities of neurological conditions through innovative research and development.
- BMB-202
In development for treating depression, anxiety, and PTSD, BMB-202 exemplifies Bright Minds Biosciences’ initiative to combat mental health disorders. Its design focuses on alleviating symptoms associated with these conditions, representing a hopeful future for many impacted by such challenges.
- BMB-201
With a specific focus on treating anxiety, BMB-201 is under development to provide relief for patients suffering from this condition. The development of this particular therapeutic highlights the company’s dedication to contributing meaningful solutions in the sphere of mental health.
In addition to these product developments, Bright Minds Biosciences maintains collaborative efforts with several research institutions, including the National Institutes of Health for epilepsy treatment, University of Texas Medical Branch for impulse control disorders, such as binge eating, and Medical College of Wisconsin. These collaborations underline the company's comprehensive approach to research and development, ensuring a broad and impactful application of its therapeutic solutions.
